Trade Report: The Karyopharm Therapeutics’ (KPTI) “Outperform” Rating Reaffirmed at Leerink Swann

The Karyopharm Therapeutics’ (KPTI) “Outperform” Rating Reaffirmed at Leerink Swann

Leerink Swann reissued their outperform rating on shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) in a research report released on Friday morning. They currently have a $18.00 price target on the stock.

Several other research firms have also recently weighed in on KPTI. Robert W. Baird reissued a positive rating and issued a $16.00 price target on shares of Karyopharm Therapeutics in a report on Tuesday, September 6th. Vetr lowered shares of Karyopharm Therapeutics from a strong-buy rating to a buy rating and set a $11.00 target price on the stock. in a research report on Wednesday, August 31st. S&P Equity Research decreased their target price on shares of Karyopharm Therapeutics from $9.06 to $7.55 in a research report on Tuesday, August 30th. Jefferies Group restated a buy rating and set a $12.00 target price on shares of Karyopharm Therapeutics in a research report on Thursday, September 8th. Finally, HC Wainwright increased their target price on shares of Karyopharm Therapeutics from $15.00 to $16.00 and gave the stock a buy rating in a research report on Thursday, September 8th. Two investment analysts have rated the stock with a sell rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus target price of $16.04.

Shares of Karyopharm Therapeutics (NASDAQ:KPTI) opened at 8.97 on Friday. The firm’s market capitalization is $322.82 million. The firm’s 50-day moving average price is $9.22 and its 200-day moving average price is $8.42. Karyopharm Therapeutics has a 12-month low of $4.83 and a 12-month high of $19.41.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings results on Thursday, August 4th. The company reported ($0.84) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.76) by $0.08. Equities analysts predict that Karyopharm Therapeutics will post ($3.22) earnings per share for the current fiscal year.

A number of institutional investors have recently made changes to their positions in KPTI. Wellington Management Group LLP increased its position in shares of Karyopharm Therapeutics by 631.9% in the first quarter. Wellington Management Group LLP now owns 1,269,485 shares of the company’s stock worth $11,323,000 after buying an additional 1,096,029 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Karyopharm Therapeutics by 29.0% in the first quarter. JPMorgan Chase & Co. now owns 280,206 shares of the company’s stock worth $2,500,000 after buying an additional 62,969 shares in the last quarter. Royal Bank of Canada increased its position in shares of Karyopharm Therapeutics by 5.1% in the first quarter. Royal Bank of Canada now owns 43,600 shares of the company’s stock worth $388,000 after buying an additional 2,126 shares in the last quarter. State Street Corp increased its position in shares of Karyopharm Therapeutics by 5.8% in the first quarter. State Street Corp now owns 360,950 shares of the company’s stock worth $3,220,000 after buying an additional 19,789 shares in the last quarter. Finally, Alliancebernstein L.P. increased its position in shares of Karyopharm Therapeutics by 24.2% in the second quarter. Alliancebernstein L.P. now owns 34,930 shares of the company’s stock worth $234,000 after buying an additional 6,800 shares in the last quarter. 55.71% of the stock is owned by institutional investors and hedge funds.

About Karyopharm Therapeutics

Related posts

Leave a Comment